GO
Loading...

Gilead Sciences Inc

More

  • Midday Glance: Biotechnology companies Thursday, 18 Sep 2014 | 1:18 PM ET

    Amgen Inc. rose$. 60 or. 4 percent, to $141.31. Biogen Idec rose $1.08 or. 3 percent, to $328.66. Celgene Corp. rose$. 66 or. 7 percent, to $92.92.

  • Final Glance: Biotechnology companies Wednesday, 17 Sep 2014 | 6:04 PM ET

    Amgen Inc. rose $1.38 or 1.0 percent, to $140.71. Biogen Idec rose$. 70 or. 2 percent, to $327.58. Celgene Corp. fell$. 31 or. 3 percent, to $92.26.

  • Rackspace and Lennar are big market movers Wednesday, 17 Sep 2014 | 4:22 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:. United States Steel Corp., up $4.20 to $45.61. Rackspace Hosting Inc., down $6.95 to $32.39.

  • Midday Glance: Biotechnology companies Wednesday, 17 Sep 2014 | 1:17 PM ET

    Amgen Inc. rose$. 55 or. 4 percent, to $139.88. Biogen Idec fell $1.90 or. 6 percent, to $324.98. Celgene Corp. fell$. 66 or. 7 percent, to $91.91.

  • Early Glance: Biotechnology companies Wednesday, 17 Sep 2014 | 10:29 AM ET

    Amgen Inc. rose$. 10 or. 1 percent, to $139.43. Biogen Idec rose$. 86 or. 3 percent, to $327.74. Celgene Corp. fell$. 02 or percent, to $92.55.

  • Study shows downward trend in Sovaldi utilization Wednesday, 17 Sep 2014 | 8:38 AM ET

    Sept 17- Over the last several months there has been a' plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000- a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. The CVS Health Research Institute analyzed discontinuation rates for nearly 2,000 patients who filled prescriptions for Sovaldi since December.

  • UPDATE 1-Gilead's experimental drug fails mid-stage study Wednesday, 17 Sep 2014 | 6:47 AM ET

    Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Separately, the biotechnology company also licensed Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.

  • GILEAD'S EXPERIMENTAL CANCER DRUG FAILS IN MID-STAGE STUDY@. Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve the length of time that patients with a type of pancreatic cancer lived without the disease worsening.

  • Final Glance: Biotechnology companies Tuesday, 16 Sep 2014 | 7:46 PM ET

    Amgen Inc. rose $1.36 or 1.0 percent, to $139.33. Biogen Idec rose $6.76 or 2.1 percent, to $326.88. Celgene Corp. rose $3.11 or 3.5 percent, to $92.57.

  • Midday Glance: Biotechnology companies Tuesday, 16 Sep 2014 | 1:22 PM ET

    Amgen Inc. rose$. 64 or. 5 percent, to $138.61. Biogen Idec rose $6.32 or 2.0 percent, to $326.44. Celgene Corp. rose $2.78 or 3.1 percent, to $92.24.

  • Early Glance: Biotechnology companies Tuesday, 16 Sep 2014 | 10:43 AM ET

    Amgen Inc. fell$. 22 or. 2 percent, to $137.75. Biogen Idec rose $4.12 or 1.3 percent, to $324.24. Celgene Corp. rose $1.18 or 1.3 percent, to $90.64.

  • Final Glance: Biotechnology companies Monday, 15 Sep 2014 | 6:03 PM ET

    Amgen Inc. rose$. 08 or. 1 percent, to $137.97. Biogen Idec fell $3.27 or 1.0 percent, to $320.12. Celgene Corp. fell $2.06 or 2.3 percent, to $89.46.

  • Business Highlights Monday, 15 Sep 2014 | 5:46 PM ET

    'Minecraft' could boost Microsoft's mobile reach. NEW YORK— Microsoft's decision to spend $2.5 billion for the creator of the hit game "Minecraft" could help the Xbox maker grab attention on mobile phones, a new priority for the company. In addition, the founders of Mojang, the Swedish company behind "Minecraft," aren't staying with Microsoft.

  • Alere and Avanir are big market movers Monday, 15 Sep 2014 | 4:33 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Alere Inc., up $4.53 to $41.14. Terex Corp., down $2.23 to $32.47.

  • Midday Glance: Biotechnology companies Monday, 15 Sep 2014 | 1:24 PM ET

    Amgen Inc. fell$. 24 or. 2 percent, to $137.65. Biogen Idec fell $6.13 or 1.9 percent, to $317.27. Celgene Corp. fell $2.40 or 2.6 percent, to $89.12.

  • NEW YORK, Sept 15- Biotech stocks were tracking for their third straight decline on Monday, weighed down by a drop in Gilead Sciences after the latest developments regarding its hepatitis C drug.

  • Early Glance: Biotechnology companies Monday, 15 Sep 2014 | 10:36 AM ET

    Amgen Inc. fell$. 84 or. 6 percent, to $137.05. Biogen Idec fell $5.40 or 1.7 percent, to $317.99. Celgene Corp. fell $2.34 or 2.6 percent, to $89.18.

  • *Gilead plans to sell Sovaldi in India for $300 a month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the $1,000- a-pill medicine in 91 developing nations.

  • *Gilead plans to sell Sovaldi in India for $300 per month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India- based drugmakers to sell cheaper versions of the $1,000- a-pill medicine in 91 developing nations including India.

  • Gilead to license generic version of Sovaldi Monday, 15 Sep 2014 | 7:40 AM ET

    Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000- per-pill hepatitis C drug Sovaldi for use in developing countries.